Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1
22 févr. 2023 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the start of a Phase 1 study evaluating its development...
Daré Bioscience to Participate in Three February Conferences
01 févr. 2023 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause
26 janv. 2023 08h00 HE
|
Daré Bioscience, Inc.
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly...
Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause
09 janv. 2023 08h00 HE
|
Daré Bioscience, Inc.
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly...
Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
12 déc. 2022 08h00 HE
|
Daré Bioscience, Inc.
DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include:...
Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health
15 nov. 2022 08h00 HE
|
Daré Bioscience, Inc.
Grant Funds Will Support Development of a Reconstitutable Vaginal Thermosetting Gel Formulation to Ultimately Serve as a Delivery Vehicle that Allows Administration of Live Biotherapeutics at the...
Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
14 nov. 2022 08h00 HE
|
Daré Bioscience, Inc.
DARE-VVA1 Demonstrated Improvement in Vaginal Cytology Parameters and Bothersome Symptoms of Vulvar and Vaginal Atrophy (VVA), Supporting Ongoing Development Investigational Therapy for Women with...
Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update
10 nov. 2022 05h45 HE
|
Daré Bioscience, Inc.
September 30, 2022: $40.4 million in cash and cash equivalentsOvaprene®: IDE approval from FDA for pivotal Phase 3 study; additional study design considerations being reviewed and implemented to...
Daré Bioscience to Present at the Stifel 2022 Healthcare Conference
08 nov. 2022 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022
03 nov. 2022 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...